malignant neuroendocrine tumors
Conditions
Interventions
Sponsors
Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)patients with histologically proven malignant neuroendocrine tumors 2)patients with metastases, recurrent lesions or unresectable lesions 3)positive I131-MIBg uptake 4)patients with written informed consent 5)patients with ADL adequate for treatment in an isolation room. patients with limited ADL which can be compensated by the others under the approval of the ethical board.
Exclusion criteria
Exclusion criteria: 1)pregnant female and feeding female 2)patients with disturbed consciousness 3)expected life interval less than 1 month 4)limited bone marrow capacity Hb<9.0, WBC count<3,000, platelet count <100,000 5)renal disorder GFR<30 ml/min/1.73 m2 6)risks for the central nerve system during treatment 7)in case that radiation safety cannot be secured. in case with uncontrolled symptoms that may require emergent medical cares. in case that understanding and cooperation cannot be obtained from family members. 8) when medical staff determine that treatment cannot be properly carried out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)assessment of anti-tumor effects with tumor size and tumor markers 2)assessment of prognosis 3)assessment of symptoms | — |
Countries
Japan
Contacts
Public ContactSeigo Kinuya
Kanazawa University Hospital Department of Nuclear Medicine
Outcome results
None listed